Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound preparation for treating nephrotic syndromes

A technology for nephrotic syndrome and compound preparations, applied in the field of medicine, can solve problems such as inconspicuous infection symptoms, spread of infection, and aggravation of nephrotic syndrome bone disease, and achieve the effects of enhancing biological effects, enhancing biological effects, and controlling disease progression.

Inactive Publication Date: 2010-10-13
中国人民解放军济南军区第四0一医院
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term or large-scale use of glucocorticoids can lead to various side effects. For example, the high protein decomposition state caused by hormones can aggravate azotemia, increase blood uric acid, induce gout and aggravate renal dysfunction; Infection symptoms may not be obvious when steroids are used, and it is easy to delay the diagnosis and spread the infection; it can also aggravate the bone disease of nephrotic syndrome, and even produce aseptic femoral neck avascular necrosis
These problems seriously affect the quality of life and prognosis of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating nephrotic syndromes
  • Compound preparation for treating nephrotic syndromes
  • Compound preparation for treating nephrotic syndromes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Scheme 1 of the present invention (group A of compound preparation): 400 mg of ginsenoside and 10 mg of prednisone.

[0013] Scheme 2 of the present invention (compound preparation B group): ginsenoside 400 mg, methylprednisone 8 mg.

[0014] It has been confirmed by clinical trials that the compound preparation can reduce the dosage of hormones to achieve the same therapeutic effect.

[0015] A randomized double-blind control design was used to collect 180 patients with nephrotic syndrome who were outpatients and inpatients in the Department of Nephrology according to the inclusion and exclusion criteria. Randomly divided into three groups:

[0016] Prednisone routine treatment group, given prednisone 15mg orally, once a day;

[0017] Compound preparation group A was given a compound preparation containing 400 mg of ginsenoside and 10 mg of prednisone orally, once a day;

[0018] The compound preparation group B was given a compound preparation containing 400 mg of ...

Embodiment 2

[0043] Scheme 3 of the present invention (compound preparation C group): ginsenoside 400mg and prednisone 20mg,

[0044] Scheme 4 of the present invention (compound preparation D group): ginsenoside 400mg and methylprednisone 16mg;

[0045] It is confirmed by clinical trials that the compound preparation can improve the curative effect of nephrotic syndrome.

[0046] A randomized double-blind control design was adopted, and 90 patients with nephrotic syndrome who visited the nephrology outpatient clinic or were hospitalized in the ward were collected according to the inclusion and exclusion criteria. They were randomly divided into three groups: prednisone routine treatment group, oral prednisone 20mg once a day; compound preparation C group, compound preparation containing ginsenoside 400mg and prednisone 20mg orally once a day; compound preparation D Group, given the compound preparation containing ginsenoside 400mg and methylprednisolone 16mg orally once a day. The curati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound preparation for treating nephrotic syndromes. A capsule of the compound preparation is prepared by combining 400 milligrams of ginsenoside and 10 to 20 milligrams of prednisone or 8 to 16 milligrams of meprednisone. The compound preparation not only enhances the biological effect of hormones, but also reduces the side effect of the hormones, so that the progress of the state of illness can be controlled more effectively. The compound preparation utilizes the effects of stress resistance, inflammatory resistance and the like of the ginsenoside used as main active ingredients of panax ginseng fully, has the two-way adjusting effect on the immunologic function and particularly has the synergistic effect on the prednisone, and is widely suitable for the treatment of autoimmune diseases.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound preparation for treating nephrotic syndrome, which consists of ginsenosides (GS) and prednisone or ginsenoside and methylprednisone in a certain proportion to form a compound preparation for more effective to treat nephrotic syndrome. Background technique [0002] Nephrotic syndrome is a group of clinical syndromes involving glomeruli characterized by massive proteinuria, hypoalbuminemia, edema with or without hyperlipidemia. The incidence of nephrotic syndrome accounts for 70% to 90% of glomerular diseases in children and 20% to 30% in adults. After treatment, the complete remission rate was 54% in children, but only 21% in adults. Renal dysfunction and renal failure are the main direction of disease progression in patients whose condition has not been completely relieved. So far, glucocorticoid (GC) represented by prednisone or methylprednisone is still the main ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/258A61P13/12A61K31/704A61K31/573
Inventor 封颖璐凌昌全
Owner 中国人民解放军济南军区第四0一医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com